A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer

Ofuji,Kazuya; Tada,Yoshitaka; Yoshikawa,Toshiaki; Shimomura,Manami; Yoshimura,Mayuko; Saito,Keigo; Nakamoto,Yasunari; Nakatsura,Tetsuya

doi:10.3892/ijo.2014.2787

A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer

Authors:
- Kazuya Ofuji
- Yoshitaka Tada
- Toshiaki Yoshikawa
- Manami Shimomura
- Mayuko Yoshimura
- Keigo Saito
- Yasunari Nakamoto
- Tetsuya Nakatsura
View Affiliations

Affiliations: Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan, Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan
Published online on: December 1, 2014 https://doi.org/10.3892/ijo.2014.2787
Pages: 497-504
Copyright: © Ofuji et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the leading cause of cancer‑related deaths worldwide. Epidermal growth factor receptor‑tyrosine kinase inhibitors (EGFR‑TKIs), such as gefitinib and erlotinib, have demonstrated marked clinical activity against non‑small cell lung cancer (NSCLC) harboring activating epidermal growth factor receptor (EGFR) mutations. However, in most cases, patients develop acquired resistance to EGFR‑TKI therapy. The threonine to methionine change at codon 790 of EGFR (EGFR T790M) mutation is the most common acquired resistance mutation, and is present in ~50% cases of TKI resistance. New treatment strategies for NSCLC patients harboring the EGFR T790M mutation are required. We evaluated the immunogenicity of an antigen derived from EGFR with the T790M mutation. Using BIMAS we selected several EGFR T790M‑derived peptides bound to human leukocyte antigen (HLA)‑A*02:01. T790M‑A peptide (789‑797) (IMQLMPFGC)‑specific cytotoxic T lymphocytes (CTLs) were induced from peripheral blood mononuclear cells (PBMCs) of HLA‑A2+ healthy donors. An established T790M‑A‑specific CTL line showed reactivity against the NCSLC cell line, H1975‑A2 (HLA‑A2+, T790M+), but not H1975 (HLA‑A2‑, T790M+), and the corresponding wild‑type peptide (ITQLMPFGC)‑pulsed T2 cells using an interferon‑γ (IFN‑γ) enzyme‑linked immuno spot (ELISPOT) assay. This CTL line also demonstrated peptide‑specific cytotoxicity against H1975‑A2 cells. This finding suggests that the EGFR T790M mutation‑derived antigen could be a new target for cancer immunotherapy.

View Figures

View References

1	Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66. 2007. View Article : Google Scholar : PubMed/NCBI
2	Youlden DR, Cramb SM and Baade PD: The international epidemiology of lung cancer: geographical distribution and secular trends. J Thorac Oncol. 3:819–831. 2008. View Article : Google Scholar : PubMed/NCBI
3	Normanno N, Maiello MR and De Luca A: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action? J Cell Physiol. 194:13–19. 2003. View Article : Google Scholar
4	Hynes NE and Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 5:341–354. 2005. View Article : Google Scholar : PubMed/NCBI
5	Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
6	Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
7	Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
8	Zhou C, Wu YL, Chen G, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
9	Rosell R, Carcereny E, Gervais R, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
10	Pao W, Miller VA, Politi KA, et al: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2:e732005. View Article : Google Scholar : PubMed/NCBI
11	Kobayashi S, Boggon TJ, Dayaram T, et al: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
12	Fujita Y, Suda K, Kimura H, et al: Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation. J Thorac Oncol. 7:1640–1644. 2012. View Article : Google Scholar : PubMed/NCBI
13	Su KY, Chen HY, Li KC, et al: Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol. 30:433–440. 2012. View Article : Google Scholar : PubMed/NCBI
14	Rosell R, Molina MA, Costa C, et al: Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res. 17:1160–1168. 2011. View Article : Google Scholar : PubMed/NCBI
15	Shepherd FA, Douillard JY and Blumenschein GR Jr: Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome. J Thorac Oncol. 6:1763–1773. 2011. View Article : Google Scholar : PubMed/NCBI
16	Rosenberg SA, Yang JC and Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat Med. 10:909–915. 2004. View Article : Google Scholar : PubMed/NCBI
17	Kawakami Y, Wang X, Shofuda T, et al: Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes. J Immunol. 166:2871–2877. 2001. View Article : Google Scholar : PubMed/NCBI
18	Lennerz V, Fatho M, Gentilini C, et al: The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci USA. 102:16013–16018. 2005. View Article : Google Scholar : PubMed/NCBI
19	Yoshikawa T, Nakatsugawa M, Suzuki S, et al: HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells. Cancer Sci. 102:918–925. 2011. View Article : Google Scholar : PubMed/NCBI
20	Valmori D, Fonteneau JF, Lizana CM, et al: Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol. 160:1750–1758. 1998.PubMed/NCBI
21	Parkhurst MR, Salgaller ML, Southwood S, et al: Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A^*0201-binding residues. J Immunol. 157:2539–2548. 1996.PubMed/NCBI
22	Fong L, Hou Y, Rivas A, et al: Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA. 98:8809–8814. 2001. View Article : Google Scholar : PubMed/NCBI
23	Hirano N, Butler MO, Xia Z, et al: Engagement of CD83 ligand induces prolonged expansion of CD8⁺ T cells and preferential enrichment for antigen specificity. Blood. 107:1528–1536. 2006. View Article : Google Scholar
24	Yoshimura M, Tada Y, Ofuzi K, Yamamoto M and Nakatsura T: Identification of a novel HLA-A^*02:01-restricted cytotoxic T lymphocyte epitope derived from the EML4-ALK fusion gene. Oncol Rep. 32:33–39. 2014.PubMed/NCBI
25	Rubio V, Stuge TB, Singh N, et al: Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med. 9:1377–1382. 2003. View Article : Google Scholar : PubMed/NCBI
26	Warren RL and Holt RA: A census of predicted mutational epitopes suitable for immunologic cancer control. Hum Immunol. 71:245–254. 2010. View Article : Google Scholar
27	Soverini S, Hochhaus A, Nicolini FE, et al: BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 118:1208–1215. 2011. View Article : Google Scholar : PubMed/NCBI
28	Cai A, Keskin DB, DeLuca DS, et al: Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients. Clin Cancer Res. 18:5761–5772. 2012. View Article : Google Scholar : PubMed/NCBI
29	Yamshchikov GV, Barnd DL, Eastham S, et al: Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients. Int J Cancer. 92:703–711. 2001. View Article : Google Scholar : PubMed/NCBI
30	Chen W, Yewdell JW, Levine RL and Bennink JR: Modification of cysteine residues in vitro and in vivo affects the immunogenicity and antigenicity of major histocompatibility complex class I-restricted viral determinants. J Exp Med. 189:1757–1764. 1999. View Article : Google Scholar : PubMed/NCBI
31	Meadows L, Wang W, den Haan JM, et al: The HLA-A^*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity. 6:273–281. 1997. View Article : Google Scholar : PubMed/NCBI
32	Shomura H, Shichijo S, Matsueda S, et al: Identification of epidermal growth factor receptor-derived peptides immunogenic for HLA-A2(+) cancer patients. Br J Cancer. 90:1563–1571. 2004. View Article : Google Scholar : PubMed/NCBI
33	Shomura H, Shichijo S, Komatsu N, et al: Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24⁺ non-small cell lung cancer patients. Eur J Cancer. 40:1776–1786. 2004. View Article : Google Scholar : PubMed/NCBI
34	Lu YC, Yao X, Li YF, et al: Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. J Immunol. 190:6034–6042. 2013. View Article : Google Scholar : PubMed/NCBI
35	Robbins PF, Lu YC, El-Gamil M, et al: Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 19:747–752. 2013. View Article : Google Scholar : PubMed/NCBI
36	Falk K, Rötzschke O, Stevanović S, Jung G and Rammensee HG: Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature. 351:290–296. 1991. View Article : Google Scholar : PubMed/NCBI
37	Sidney J, Southwood S, Mann DL, Fernandez-Vina MA, Newman MJ and Sette A: Majority of peptides binding HLA-A^*0201 with high affinity crossreact with other A2-supertype molecules. Hum Immunol. 62:1200–1216. 2001. View Article : Google Scholar : PubMed/NCBI
38	Matsushita H, Vesely MD, Koboldt DC, et al: Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 482:400–404. 2012. View Article : Google Scholar : PubMed/NCBI
39	Schirle M, Keilholz W, Weber B, et al: Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. Eur J Immunol. 30:2216–2225. 2000. View Article : Google Scholar : PubMed/NCBI
40	Parkhurst MR, Riley JP, Igarashi T, Li Y, Robbins PF and Rosenberg SA: Immunization of patients with the hTERT:540–548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin Cancer Res. 10:4688–4698. 2004. View Article : Google Scholar : PubMed/NCBI
41	Matar P, Alaniz L, Rozados V, et al: Immunotherapy for liver tumors: present status and future prospects. J Biomed Sci. 16:302009. View Article : Google Scholar : PubMed/NCBI
42	Pollack BP, Sapkota B and Cartee TV: Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes. Clin Cancer Res. 17:4400–4413. 2011. View Article : Google Scholar : PubMed/NCBI
43	He S, Yin T, Li D, et al: Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation. J Transl Med. 11:1862013. View Article : Google Scholar : PubMed/NCBI
44	Yamada T, Azuma K, Muta E, et al: EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A^*0201-restricted T cell epitopes derived from the EGFR T790M mutation. PLoS One. 8:e783892013. View Article : Google Scholar